Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

China’s Junshi Biosciences yesterday revealed that its wholly-owned subsidiary TopAlliance Bioscience has entered into a ...